What it's for (Indications)
- Priorix-Tetra is indicated for active immunization against measles, mumps, rubella, and varicella (chickenpox) in individuals from 12 months up to 12 years of age.
- This live attenuated combined vaccine aims to provide simultaneous protection against these four common childhood infectious diseases, which can have serious complications.
- The vaccine is administered to susceptible children to prevent the onset of these diseases by inducing a robust and long-lasting immune response.
- The primary goal is to establish active immunity, significantly reducing the incidence and severity of these vaccine-preventable illnesses within the target population, aligning with national immunization programs and public health objectives for disease eradication and control.
- The decision to use this combined vaccine versus separate MMR and varicella vaccines should consider national recommendations and individual patient risk factors, particularly regarding febrile seizures.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage for Priorix-Tetra is a single 0.5 mL dose administered subcutaneously. The immunization schedule typically involves two doses for comprehensive protection. The first dose is generally recommended for children aged 12 to 15 months. The second dose is usually administered at 4 to 6 years of age, or at least 3 months after the initial dose, depending on specific national immunization guidelines and local epidemiological considerations. It is crucial to adhere strictly to the recommended age ranges and intervals between doses to ensure optimal seroconversion and sustained immunity. For children aged 12 to 23 months, particular attention should be given to the choice of vaccine (MMRV vs. separate MMR and varicella) due to a slightly increased risk of febrile seizures with the first dose of MMRV, as detailed in the warnings section. Healthcare professionals must ensure proper vaccine preparation and aseptic injection techniques. |
Safety & Warnings
Common Side Effects
- Common side effects associated with Priorix-Tetra typically include local reactions at the injection site such as pain, redness, and swelling, which are generally mild and transient.
- Systemic reactions may include fever (often low-grade but can be higher), irritability, loss of appetite, and a rash that may resemble measles, rubella, or varicella.
- Less common adverse events can involve lymphadenopathy, parotitis (swelling of the salivary glands), diarrhea, vomiting, and otitis media.
- A notable but rare risk is febrile seizures, which have been observed at a higher rate when Priorix-Tetra is administered as the first dose to children aged 12-23 months compared to separate MMR and varicella vaccines.
- Very rare but serious adverse reactions can include thrombocytopenic purpura, encephalitis, and aseptic meningitis, though these are extremely uncommon.
- Anaphylaxis or other severe allergic reactions are also rare but require immediate medical attention.
- Parents and caregivers should be informed about potential side effects and when to seek medical advice following vaccination.
Serious Warnings
- Black Box Warning: While Priorix-Tetra does not carry a formal FDA Black Box Warning, a serious safety concern that warrants careful consideration and patient counseling involves the increased risk of febrile seizures. Specifically, in children aged 12 to 23 months, the incidence of febrile seizures is higher when the Measles, Mumps, Rubella, and Varicella (MMRV) vaccine is administered as the first dose compared to administering the Measles, Mumps, and Rubella (MMR) vaccine and the monovalent Varicella (V) vaccine as separate injections on the same day. This elevated risk is primarily observed in the 5 to 12 days following vaccination. Healthcare providers must discuss this specific risk with parents and guardians of eligible children to ensure informed decision-making regarding vaccination options. Alternative vaccination strategies, such as administering MMR and varicella vaccines separately, may be considered for this age group to mitigate this elevated risk, in accordance with national immunization guidelines and clinical best practices. Close monitoring for fever and febrile seizures after vaccination is recommended, especially in children with a history of seizures or a family history of febrile seizures.
- Healthcare providers should be acutely aware of specific warnings associated with Priorix-Tetra.
- A critical consideration is the increased risk of febrile seizures in children aged 12-23 months when they receive their first dose of MMRV vaccine compared to receiving separate MMR and varicella vaccines on the same day.
- This risk should be discussed with parents and caregivers.
- The vaccine should be deferred in individuals with moderate or severe acute illness.
- Special caution is advised for individuals with a history of seizures or a family history of seizures; a thorough risk-benefit assessment is essential.
- Individuals with thrombocytopenia or any coagulation disorder should receive the vaccine with caution, as bleeding may occur following intramuscular or subcutaneous administration.
- Syncopal episodes (fainting) can occur post-vaccination, potentially leading to injury from falls, thus patients should be monitored.
- There is a theoretical risk of vaccine virus transmission to susceptible contacts from varicella-vaccinated individuals, though documented cases are exceedingly rare.
- Women of childbearing potential should be advised to avoid pregnancy for at least one month after vaccination due to the live attenuated viral components.
- Allergic reactions, including anaphylaxis, can occur, and appropriate medical treatment should be readily available during administration.
How it Works (Mechanism of Action)
Priorix-Tetra is a live attenuated viral vaccine containing weakened strains of measles (Schwarz strain), mumps (RIT 4385 strain, derived from Jeryl Lynn), rubella (Wistar RA 27/3 strain), and varicella (Oka/Merck strain) viruses. Upon subcutaneous administration, these attenuated viruses replicate in the host, albeit to a limited extent, without causing the full-blown disease. This replication process mimics a natural infection, stimulating both humoral (antibody-mediated) and cell-mediated immune responses. The body's immune system recognizes the viral antigens and produces specific antibodies (e.g., IgG, IgM) and T-lymphocytes against each component. This leads to the development of active immunity and immunological memory, providing long-term protection against subsequent infection with wild-type measles, mumps, rubella, and varicella viruses. The attenuated nature of the viruses ensures that the vaccine elicits an immune response effectively and safely, without inducing severe disease symptoms.
Commercial Brands (Alternatives)
No other brands found for this formula.